Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cytidine deaminase and the development of resistance to arabinosyl cytosine.

× No keyword cloud information.

43 in total

1. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.

Authors: J Laliberté; V E Marquez; R L Momparler
Journal: Cancer Chemother Pharmacol Date: 1992 Impact factor: 3.333

2. Combination chemotherapy.

Authors: T A Connors
Journal: Proc R Soc Med Date: 1974-06

Review 3. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors: Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal: Semin Oncol Date: 2012-02 Impact factor: 4.929

Review 4. Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors: W Hiddemann
Journal: Ann Hematol Date: 1991-04 Impact factor: 3.673

Review 5. Resistance to cytostatic drugs at the cellular level.

Authors: C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal: Cancer Chemother Pharmacol Date: 1992 Impact factor: 3.333

6. Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells.

Authors: Hongmei Ruan; Songbo Qiu; Brian C Beard; Margaret E Black
Journal: Protein Eng Des Sel Date: 2016-05-08 Impact factor: 1.650

7. A rearrangement of the CDD gene at the 5' UTR produces two types of transcripts that contain a natural antisense region.

Authors: H Jung-Ha; Y Lee; D Kim; B H Song
Journal: Mol Biol Rep Date: 1998-11 Impact factor: 2.316

8. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).

Authors: Amy E DeZern; Amer M Zeidan; John Barnard; Wesley Hand; Najla Al Ali; Francis Brown; Cassie Zimmerman; Gail J Roboz; Guillermo Garcia-Manero; David P Steensma; Rami S Komrokji; Mikkael A Sekeres
Journal: Leuk Lymphoma Date: 2016-10-24

9. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.

Authors: Gautam Borthakur; Xuelin Huang; Hagop Kantarjian; Stefan Faderl; Farhad Ravandi; Alessandra Ferrajoli; Ritva Torma; Gail Morris; Donald Berry; Jean-Pierre Issa
Journal: Leuk Lymphoma Date: 2010-01

10. Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

Authors: D H Horber; H Schott; R A Schwendener
Journal: Cancer Chemother Pharmacol Date: 1995 Impact factor: 3.333